Furthermore, EGF-treated USP11-KO CRC cells displayed substantially lower proliferation rates than EGF-treated control cells (Fig. 2I, USP11-KO HCT-15 treated with EGF vs. Ctrl HCT-15 treated with EGF; Fig. 2J, USP11-KO HT-29 treated with EGF vs. Ctrl HT-29 treated with EGF). This evidence concerns the gene EGF and colorectal carcinoma.